NBIX
Neurocrine Biosciences Inc
138.40$
-0.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 81.6% | 80.9% | 85.0% | 67.9% | 74.3% | 63.6% | 58.6% | 46.9% | 61.4% | 49.4% | 46.4% | 54.5% | |
| 12.8% | 15.6% | 22.8% | 31.2% | 14.3% | 8.6% | 10.8% | 16.4% | 11.1% | 7.7% | 6.3% | 15.4% | |
| 79.7% | 79.9% | 84.2% | 63.1% | 65.5% | 51.3% | 46.2% | 34.3% | 41.8% | 31.7% | 28.9% | 32.0% | |
| – | – | – | 3.8% | 5.7% | 9.7% | 9.1% | 9.0% | 14.8% | 13.5% | 12.9% | 14.8% | |
| 0.0% | 0.0% | 0.0% | -3.8% | 1.1% | 1.3% | 1.6% | 1.5% | 1.5% | 1.2% | 1.5% | 1.5% | |
| 1.0% | 0.7% | 1.7% | 1.3% | 3.4% | 3.2% | 2.6% | 2.8% | 2.5% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | 0.2% | 0.2% | 0.2% | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 1.1% | 1.0% | – | – | 1.6% | 1.1% | 1.0% | – | |
| 14.1% | 10.6% | 13.8% | 54.5% | 51.6% | 51.2% | 35.1% | 33.7% | 27.9% | 31.4% | 30.4% | 29.8% | |
| 6.4% | 5.4% | 8.3% | 6.7% | 8.9% | 43.3% | 10.8% | 11.9% | 22.7% | 20.1% | 13.7% | 16.1% | |
| – | 2.6% | 4.1% | 4.7% | 6.3% | 31.3% | 0.6% | 0.8% | 7.2% | 5.2% | – | – | |
| 0.1% | 0.5% | 1.4% | 0.7% | 1.4% | 3.5% | 2.3% | 2.5% | 2.8% | 4.1% | 2.7% | 2.3% | |
| 0.0% | 0.0% | 0.0% | 45.2% | 39.1% | 31.3% | 18.3% | 16.2% | – | – | – | – | |
| 85.9% | 89.4% | 86.2% | 45.5% | 48.4% | 48.8% | 64.9% | 66.3% | 72.1% | 68.6% | 69.6% | 70.2% | |
| -340.0% | -192.8% | -289.3% | -146.6% | -118.6% | -86.7% | -41.8% | -30.7% | -17.2% | -4.8% | 0.8% | 9.7% | |
| 30.7% | 17.8% | 23.8% | 10.8% | 9.6% | 7.3% | 5.6% | 4.7% | 4.2% | 3.1% | 2.8% | 2.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.